In COVID-19 clinical update #90, Dr. Griffin covers FDA expansion for booster doses, 3 more at home antigen tests approved by FDA, immune correlates analysis of mRNA-1273 vaccine, risk for stillbirth, PROVENT prophylaxis trial results, fluvoxamine recommendations, advice on molnupiravir, automated text messaging service for monitoring illness, and long COVID-19 after vaccination and infection.

Hosts: Daniel Griffin and Vincent Racaniello

Subscribe (free): iTunes, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Expanded eligibility for booster doses (FDA)
• More rapid antigen tests approved (FDA)
• Immune correlates for mRNA-1273 (Science)
• Risk for still birth with and without COVID-19 (MMWR)
• PROVENT phase III prophylaxis trial (AstraZenica)
• Fluvoxamine guidelines (IDSA)
• COVID-OUT trial (Univ Minnesota)
• Monoclonal antibody treatment in vaccinated infected (J Inf Dis)
• Steroid use in non-oxygen requiring patients (QJM)
• Doxycycline trial (Lancet)
• Efficacy of inhaled ciclesonide (JAMA)
• Advise on use of molnupiravir (EMA)
• Text messaging for monitoring disease (Ann Int Med)
• Long COVID after vaccination and infection (Res Square)
• Ivermectin for West Nile virus (Medpage Today)
• Letters read on TWiV 834
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]